Published in JAMA Network Open · View the paper (DOI)
A recent study found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than doubled from 2022 to 2023, while rates of metabolic bariatric surgery dropped by one quarter. This shift in treatment options has implications for access to comprehensive multidisciplinary care for obesity.
Coverage from 2 institutions